News Conference News VIVA 2022 TRANSCEND: Low-Dose DCB for PAD Still Looking Good at 2 Years L.A. McKeown November 03, 2022
News Daily News IVUS Useful in Many Peripheral Intervention Scenarios, Consensus Document L.A. McKeown August 05, 2022
News Daily News Five-Year Paclitaxel DCB Data Attest to Long-term Safety, Efficacy L.A. McKeown June 01, 2022
News Conference News SCAI 2022 DISRUPT PAD III: Lithotripsy Prep Linked to Better PAD Patency at 1 Year L.A. McKeown May 23, 2022
News Conference News SCAI 2022 SAFE-PAD Provides More Long-term Safety Data for Paclitaxel L.A. McKeown May 22, 2022
News Daily News Good News and Bad for High-Intensity Statin Use in ASCVD Michael O'Riordan May 05, 2022
News Conference News ACC 2022 Second-Generation Chocolate Touch DCB Bests Lutonix for Patency in PAD L.A. McKeown April 04, 2022